Australia's most trusted
source of pharma news
Posted 12 March 2026 AM
Sydney-based pharma Phebra has launched heart drug Rapiblyk in Australia.
Rapiblyk, an ultra-short acting, cardio-selective receptor antagonist developed by Austrian pharma AOP Orphan Health, was approved by the TGA in June last year, indicated for supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.